Farber HW - Search Results

1

Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy.

Abston E, Farber HW. Abston E, et al. Among authors: farber hw. Pulm Pharmacol Ther. 2019 Aug;57:101813. doi: 10.1016/j.pupt.2019.101813. Epub 2019 Jun 12. Pulm Pharmacol Ther. 2019. PMID: 31199984

2

Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.

Farber HW, Graven KK, Kokolski G, Korn JH. Farber HW, et al. J Rheumatol. 1999 May;26(5):1195-6. J Rheumatol. 1999. PMID: 10332990

3

Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).

Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Klings ES, et al. Among authors: farber hw. Arthritis Rheum. 1999 Dec;42(12):2638-45. doi: 10.1002/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X. Arthritis Rheum. 1999. PMID: 10616012 Free article.

4

Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

Aguilar RV, Farber HW. Aguilar RV, et al. Among authors: farber hw. Am J Respir Crit Care Med. 2000 Nov;162(5):1846-50. doi: 10.1164/ajrccm.162.5.2004042. Am J Respir Crit Care Med. 2000. PMID: 11069824

5

Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.

Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Preston IR, et al. Among authors: farber hw. Respir Med. 2005 Dec;99(12):1501-10. doi: 10.1016/j.rmed.2005.03.026. Respir Med. 2005. PMID: 15890512 Free article. Clinical Trial.

6

Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension.

Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Klinger JR, et al. Among authors: farber hw. Chest. 2006 Feb;129(2):417-425. doi: 10.1378/chest.129.2.417. Chest. 2006. PMID: 16478861

7

Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.

Steiner MK, Preston IR, Klinger JR, Criner GJ, Waxman AB, Farber HW, Hill NS. Steiner MK, et al. Among authors: farber hw. Chest. 2006 Nov;130(5):1471-80. doi: 10.1378/chest.130.5.1471. Chest. 2006. PMID: 17099026 Clinical Trial.

8

Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.

Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Fisher KA, et al. Among authors: farber hw. Chest. 2006 Nov;130(5):1481-8. doi: 10.1378/chest.130.5.1481. Chest. 2006. PMID: 17099027

9

Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension.

Hardy H, Backman ES, Farber HW. Hardy H, et al. Among authors: farber hw. Pharmacotherapy. 2010 Apr;30(4):139e-44e. doi: 10.1592/phco.30.4.422. Pharmacotherapy. 2010. PMID: 20334465

10

Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.

Walkey AJ, Fein D, Horbowicz KJ, Farber HW. Walkey AJ, et al. Among authors: farber hw. Pulm Pharmacol Ther. 2011 Aug;24(4):421-5. doi: 10.1016/j.pupt.2011.01.002. Epub 2011 Jan 18. Pulm Pharmacol Ther. 2011. PMID: 21251994

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters